Engineered immune cells take on tough lymphoma in new trial

NCT ID NCT04531046

Ongoing Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified in a lab to better attack cancer cells. The main goal is to see how many patients achieve a complete response, meaning no signs of cancer remain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axicabtagene ciloleucel (axi-cel), a CAR T-cell therapy made from the patient's own immune cells
What this could lead to: If successful, this could offer a powerful treatment option for people with aggressive B-cell lymphoma who cannot have a stem cell transplant.
What could go wrong: This is a mid-stage trial with only 62 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma indolent B-cell non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL LYMPHOMA RECURRENT B-CELL LYMPHOMA REFRACTORY

Contacts and locations

Locations

APHP - Hôpital Henri Mondor

Créteil, France
APHP - Hôpital Saint Louis

Paris, 75475, France
CH Liège

Liège, 4000, Belgium
CHU Brabois

Vandœuvre-lès-Nancy, 54511, France
CHU Clermont Ferrand - Hôpital Estaing

Clermont-Ferrand, France
CHU de Bordeaux - Hôpital Haut Lévêque

Bordeaux, France
CHU de Dijon - Hôpital le Bocage

Dijon, 21000, France
CHU de Nantes - Hôtel Dieu

Nantes, 44093, France
CHU de Rennes - Hôpital de Pontchaillou

Rennes, 35003, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Hopital La Pitié Salpétriere

Paris, France
Hôpital Claude Huriez

Lille, 59037, France
Hôpital Saint Antoine

Paris, France
Hôpital Saint Eloi

Montpellier, 34295, France
IUCT Oncopole

Toulouse, France
Institut de Cancérologie Gustave Roussy

Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.